Literature DB >> 16714545

Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection.

Korana Musicki1, Helen Briscoe, Stephen Tran, Warwick J Britton, Bernadette M Saunders.   

Abstract

The relative contributions of transmembrane tumor necrosis factor (memTNF) and soluble tumor necrosis factor (solTNF) in innate and adaptive immunity are poorly defined. We examined the capacities of wild-type (WT) mice, TNF-/- mice, and memTNF mice, which express only transmembrane TNF, to control primary and secondary Listeria monocytogenes infections. Soluble TNF was not required for induction or maintenance of protective immunity against a low-dose (200-CFU) Listeria infection. In contrast to TNF-/- mice, both WT and memTNF mice cleared the bacilli within 10 days and were fully protected against rechallenge with a lethal infective dose. Furthermore, T cells transferred from immune mice, but not from naïve, WT, and memTNF mice, protected TNF-/- recipients against an otherwise lethal infection. By contrast, infection with a higher dose of Listeria (2,000 CFU) clearly demonstrated that solTNF is required to coordinate an optimal protective inflammatory response. memTNF mice were more susceptible to a high-dose infection, and they exhibited delayed bacterial clearance, increased inflammation, and necrosis in the liver that resulted in 55% mortality. The dysregulated inflammation was accompanied by prolonged elevated expression of mRNAs for several chemokines as well as the macrophage effector molecules inducible nitric oxide synthase and LRG-47 in the livers of memTNF mice but not in the livers of WT mice. These data demonstrated that memTNF is sufficient for establishing protective immunity against a primary low-dose Listeria infection but that solTNF is required for optimal control of cellular inflammation and resistance to a primary high-dose infection. By contrast, memTNF alone is sufficient for resolution of a secondary, high-dose infection and for the transfer of protective immunity with memory T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714545      PMCID: PMC1479262          DOI: 10.1128/IAI.02004-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Tumor necrosis factor: a master-regulator of leukocyte movement.

Authors:  J D Sedgwick; D S Riminton; J G Cyster; H Körner
Journal:  Immunol Today       Date:  2000-03

Review 2.  The TNF and TNF receptor superfamilies: integrating mammalian biology.

Authors:  R M Locksley; N Killeen; M J Lenardo
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 3.  Antimicrobial reactive oxygen and nitrogen species: concepts and controversies.

Authors:  Ferric C Fang
Journal:  Nat Rev Microbiol       Date:  2004-10       Impact factor: 60.633

4.  Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

Authors:  Maria L Olleros; Reto Guler; Nadia Corazza; Dominique Vesin; Hans-Pietro Eugster; Gilles Marchal; Pierre Chavarot; Christoph Mueller; Irene Garcia
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

5.  Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Authors:  S R Ruuls; R M Hoek; V N Ngo; T McNeil; L A Lucian; M J Janatpour; H Körner; H Scheerens; E M Hessel; J G Cyster; L M McEvoy; J D Sedgwick
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

6.  Lethal granuloma disintegration in mycobacteria-infected TNFRp55-/- mice is dependent on T cells and IL-12.

Authors:  S Ehlers; S Kutsch; E M Ehlers; J Benini; K Pfeffer
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

7.  Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Authors:  Bernie Scallon; Ann Cai; Nancy Solowski; Amy Rosenberg; Xiao-Yu Song; David Shealy; Carrie Wagner
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

Review 8.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 9.  Biological functions of tumor necrosis factor cytokines and their receptors.

Authors:  Klaus Pfeffer
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

10.  Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection.

Authors:  C M Collazo; G S Yap; G D Sempowski; K C Lusby; L Tessarollo; G F Vande Woude; A Sher; G A Taylor
Journal:  J Exp Med       Date:  2001-07-16       Impact factor: 14.307

View more
  7 in total

1.  Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon.

Authors:  Teresa M Wozniak; Bernadette M Saunders; Anthony A Ryan; Warwick J Britton
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

Review 2.  TNF activity and T cells.

Authors:  Amit K Mehta; Donald T Gracias; Michael Croft
Journal:  Cytokine       Date:  2016-08-13       Impact factor: 3.861

3.  Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules.

Authors:  Maria L Olleros; Dominique Vesin; Ruth Bisig; Marie-Laure Santiago-Raber; Sonia Schuepbach-Mallepell; George Kollias; Olivier Gaide; Irene Garcia
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

4.  Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.

Authors:  Nadia Belmellat; Luca Semerano; Noria Segueni; Diane Damotte; Patrice Decker; Bernhard Ryffel; Valérie Quesniaux; Marie-Christophe Boissier; Eric Assier
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

5.  Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice.

Authors:  Minna Yli-Karjanmaa; Bettina Hjelm Clausen; Matilda Degn; Hans Gram Novrup; Ditte Gry Ellman; Peter Toft-Jensen; David E Szymkowski; Allan Stensballe; Morten Meyer; Roberta Brambilla; Kate Lykke Lambertsen
Journal:  Front Neurosci       Date:  2019-08-07       Impact factor: 4.677

Review 6.  Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.

Authors:  Roman Fischer; Roland E Kontermann; Klaus Pfizenmaier
Journal:  Front Cell Dev Biol       Date:  2020-05-26

Review 7.  Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.

Authors:  Sujuan Yang; Julie Wang; David Douglass Brand; Song Guo Zheng
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.